Search Thermo Fisher Scientific
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Progesterone Receptor Monoclonal Antibody (KMC912), eBioscience™
FIGURE: 1 / 2
Progesterone Receptor Antibody (14-9764-82) in ICC/IF
Immunocytochemistry of fixed and permeabilized MCF7 cells using 1 µg/mL of Anti-Human Progesterone Receptor Purified followed by 1 µg/mL of F (ab')2 Anti-Mouse IgG eFluor® 570.Nuclei are counterstained with DAPI, and colocalization of signal appears pink.
Product Details
14-9764-82
Applications
Tested Dilution
Publications
Product Specifications
Species Reactivity
Human
Host/Isotype
Mouse
/ IgG1, kappa
Class
Monoclonal
Type
Antibody
Clone
KMC912
Conjugate
Form
Liquid
Concentration
0.5 mg/mL
Purification
Affinity chromatography
Storage buffer
PBS, pH 7.2
Contains
0.09% sodium azide
Storage conditions
4° C
Shipping conditions
Ambient (domestic); Wet ice (international)
RRID
AB_2573004
Product Specific Information
Description: This KMC912 monoclonal antibody reacts with human progesterone receptor (PgR, PR), a member of a superfamily of nuclear receptors that are ligand-dependent transcriptional regulators. The human PgR exists in alpha and beta forms, 94 kDa and 120 kDa respectively. In most human cells, the alpha and beta forms are expressed at similar levels and predominately form heterodimers. Progestin binding to PgR causes a conformational change, allowing dissociation of bound chaperone proteins and subsequent dimerization with either PgRa or PgRb. Following activation, dimerized PgR can directly bind to DNA through progestin response elements (PRE) leading to chromatin remodeling and subsequent downregulation or transcription of the target gene.The PgR plays a key role in controlling gene expression in breast, uterine, brain, and cardiovascular tissue during development. The presence of the PgR in breast tissue is indicative of improved survival and a better response to endocrine therapy. In breast and endometrial cancer progression, a predominance of either the alpha or beta form occurs, suggesting disregulation in the PgRa:PgRb ratio is an early event in cancer. In cases of ductal carcinoma in situ and invasive ductal carcinoma, there is predominance of the alpha form while in uterine cancer a loss of either form is common.
Applications Reported: This KMC912 antibody has been reported for use in immunohistochemical staining of formalin-fixed paraffin embedded tissue sections, microscopy, and immunocytochemistry.
Applications Tested: This KMC912 antibody has been tested by immunohistochemistry of formalin-fixed paraffin embedded human tissue using high or low pH antigen retrieval and can be used at less than or equal to 2.5 µg/mL. This KMC912 antibody has been tested by immunocytochemistry of methanol-fixed or formaldehyde-fixed and permeabilized human cells and can be used at less than or equal to 1 µg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
Purity: Greater than 90%, as determined by SDS-PAGE.
Aggregation: Less than 10%, as determined by HPLC.
Filtration: 0.2 µm post-manufacturing filtered.
Target Information
The progesterone receptor (PR) is a member of the steroid family of nuclear receptors. The PR mediates the physiological effects of progesterone, which plays a central role in reproductive events associated with the establishment and maintenance of pregnancy. PR is found as a 94 kDa protein (Form A) or a 120 kDa protein (Form B) due to the use of alternative translation initiation sites. PR-B is the transcriptionally active form and is responsible for activating genes for the maintenance of the endometrium, maintenance of pregnancy, and inhibition of ovulation. PR-A is identical to PR-B except for a 165 amino acid deletion at the N-terminus. This deletion exposes a 140 amino acid inhibitory domain (ID) that acts as a repressor of steroid hormone transcriptional activity. In its inactive state, PgR forms a multiprotein complex which includes heat shock proteins and immunophins. Upon binding of progesterone hormone to its receptor, there is a conformational change that allows dimerization and binding of the receptor to progesterone response elements (PRE) sequences, resulting in activated transcription. A Null mutation in the PGR gene leads to pleiotrophic reproductive abnormalities.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Bioinformatics
Protein Aliases: Nuclear receptor subfamily 3 group C member 3; PR; Progesterone receptor
Gene Aliases: NR3C3; PGR; PR
UniProt ID: (Human) P06401
Entrez Gene ID: (Human) 5241
RNA polymerase II core promoter proximal region sequence-specific DNA binding
transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
DNA binding
steroid hormone receptor activity
steroid binding
protein binding
zinc ion binding
enzyme binding
ATPase binding
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support